SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is experiencing significant price volatility, largely attributed to geopolitical concerns impacting major South Korean memory producers, despite strong bullish sentiment surrounding its sold-out High-Bandwidth Memory (HBM) supply for AI infrastructure through 2027 and recent analyst target increases.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

Invesco QQQ Trust is trending as the escalating Middle East conflict and its impact on global oil supplies fuel market volatility, leading to intense community discussion around the US market's perceived resilience and "V-shaped" recoveries despite significant sell-offs in Asian markets.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is trending amidst escalating geopolitical tensions in the Middle East, with community discussion focused on the potential for a prolonged conflict and its impact on global oil supply. Traders are actively debating whether the market's current volatility will lead to a significant downturn, particularly given sharp declines observed in Asian markets.

SSgA Active Trust - State Street SPDR Dow Jones Industrial Average ETF Trust

The SPDR Dow Jones Industrial Average ETF is actively discussed amid escalating US-Israel-Iran tensions and concerns over oil supply, creating a divided community perspective between those fearing a broader market downturn and others anticipating a resilient "buy the dip" bounce.

Alibaba Group Holding Ltd. engages in providing technology infrastructure and marketing reach. It operates through the following business segments: China Commerce, International Commerce, Local Consumer Services, Cainiao, Cloud, Digital Media and Entertainment, and Innovation Initiatives and Others segments. The Core Commerce segment consists of platforms operating in retail and wholesale. The China Commerce segment includes China commerce retail and wholesale businesses. The International Commerce segment focuses on international commerce retail and wholesale businesses. The Local Consumer Services segment is involved in To-Home businesses, which include Ele.me, local services and delivery platform, and Taoxianda, and To-Destination segment businesses which include Amap, the provider of mobile digital map, navigation and real-time traffic information, and restaurant and local services guide platform. The Cainiao segment has Cainiao Network and offers domestic and international one-stop-shop logistics services and supply chain management solution. The Cloud segment includes Alibaba Cloud and DingTalk. The company was founded by Chung Tsai and Yun Ma on June 28, 1999 and is headquartered in Hangzhou, China.

Alibaba Group Holding Ltd - ADR

Alibaba Group Holding Ltd

Alibaba is trending amidst significant volatility driven by its delayed earnings report, which fuels investor uncertainty, alongside recent geopolitical noise, including the briefly reinstated Pentagon list and ongoing tariff discussions. Despite this, the launch of its upgraded Qwen 3.5 AI model and deeply oversold technicals are sparking community debate over whether it presents a compelling 'buy the dip' opportunity.

JD.com, Inc. is a technology-driven E-commerce company, which engages in the sale of electronics products and general merchandise products, including audio, video products, and books. It operates in the following segments: JD Retail, JD Logistics, and New Businesses. The JD Retail segment offers online retail, online marketplace, and marketing services. The JD Logistics segment includes internal and external logistics businesses. The New Businesses segment is composed of JD Property, Jingxi, overseas businesses and technology initiatives. The company was founded on June 18, 1998, by Qiang Dong Liu and is headquartered in Beijing, China.

JD.com Inc - ADR

JD.com is experiencing extreme community frustration due to its persistent underperformance and new 52-week lows, with many questioning management's strategy and the impact of intense market competition. Investors are keenly anticipating upcoming earnings to see if deep undervaluation, fueled by substantial cash and revenue, will finally translate into a turnaround, or if further declines are in store.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

SELLAS Life Sciences is trending due to heightened community speculation about a significant buyout by a major pharmaceutical company, fueled by optimism that its GPS cancer treatment is showing exceptional patient survival in its ongoing Phase 3 trial and a potential short squeeze given high interest.

Brand Engagement Network, Inc. engages in the provision of conversational artificial intelligence assistants with the purpose of transforming engagement and analytics for businesses through security-focused, multimodal communication and human-like artificial intelligence assistants. The firm is also involved in delivering highly personalized, multi-modal artificial intelligence engagement with a focus on industries where there is a massive workforce gap and an opportunity to transform how consumers engage with networks, providers, and brands. The company is founded on March 14, 2024 and is headquartered in Jackson, WY.

Brand Engagement Network Inc

Brand Engagement Network Inc. is attracting significant attention due to a recent press release and live product deployment, with the community actively speculating on a potential short squeeze. Elevated short interest and exorbitant cost-to-borrow rates are fueling this buzz, as many anticipate continued strong performance.

GitLab, Inc. engages in the intelligent DevSecOps platform for software innovation. The firm enables organizations to increase developer productivity, improve operational efficiency, reduce security and compliance risk, and accelerate digital transformation. The company was founded by Dmitriy Zaporozhets and Sid Sijbrandij in 2011 and is headquartered in San Francisco, CA.

Gitlab Inc - Ordinary Shares - Class A

Gitlab Inc

GitLab is actively discussed following its earnings report, which, despite beating some estimates and announcing a $400 million share repurchase, also included weaker guidance on future growth, sparking a polarized reaction. While many express concern over slowing growth and potential competition from AI, others view the sell-off as an overreaction and are keenly watching for a potential acquisition amidst persistent buyout rumors.

Kamino Finance was originally created to offer users the easiest possible way of providing liquidity and earning yield on-chain.  The protocol's one-click, auto-compounding concentrated liquidity strategies quickly became the most popular LP products on Solana, and laid the foundation for what Kamino is now.  Today, Kamino is a first-of-its-kind DeFi protocol that unifies Lending, Liquidity, and Leverage into a single, secure DeFi product suite.

Kamino

KMNO Crypto is generating significant buzz following its partnership with Anchorage Digital Bank, which integrates regulated custody with Solana's on-chain lending, driving a notable increase in volume. The community is actively discussing its low market cap and strong fundamentals as a leading DeFi protocol on Solana, positioning it as a potential "sleeping giant" for substantial growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Wall Street closed lower across the board on Tuesday, with the Dow falling 0.8%, the S&amp;P 500 dropping 0.9%, and the Nasdaq sliding 1%.</li><li>Energy markets drove much of the volatility, with Brent and WTI crude jumping by more than 4.5% each.</li><li>Trump said the U.S. could help stabilize shipping lanes by providing insurance guarantees and, potentially, naval escorts for vessels traveling through the Strait of Hormuz.</li></ul>U.S. stock futures traded lower late Tuesday after a volatile session on Wall Street as escalating tensions in the Middle East and a surge in oil prices rattled investor sentiment.As of 9.17 p.m. ET, Nasdaq 100 and S&amp;P 500 futures were down 0.4% each, while Dow futures were down 0.3%.On Stocktwits, retail sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF Trust (SPY)</a> and&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust (QQQ)</a> was ‘bearish’ amid ‘high’ message volume, and sentiment toward the&nbsp;<a href="https://stocktwits.com/symbol/DIA">SPDR Dow Jones Industrial Average ETF Trust (DIA)</a> was ‘neutral’ amid ‘high’ message volume.<h2 class="st-heading-2">US Market Drivers</h2>Markets reacted to escalating concerns around the ongoing U.S.-Iran conflict after renewed attacks across the Middle East raised fears of prolonged disruptions to global energy supplies.In the prior session, the Dow Jones Industrial Average fell 0.8%, while the S&amp;P 500 slipped 0.9% and the Nasdaq Composite dropped 1%. All 11 sectors in the S&amp;P 500 finished lower. Materials was the worst-performing sector, falling about 2.5%, followed by industrials, which declined 1.9%.Ryan Detrick, Chief Market Strategist at Carson Group,&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/RyanDetrick/status/2028845602017353765">said on X</a> that it was a “good reminder that we just had the smallest first two-month range EVER for the S&amp;P 500. Tight ranges don't last forever.”Investor concerns increased after Iran’s Revolutionary Guard threatened to target ships attempting to transit the strait. Tanker traffic through the route largely halted as the conflict escalated.&nbsp;U.S.President Donald Trump said on Tuesday that the U.S. would provide insurance guarantees and potentially naval escorts to vessels traveling through the Strait of Hormuz to ensure energy shipments continue. “No matter what, the United States will ensure the FREE FLOW of ENERGY to the WORLD,” Trump&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://truthsocial.com/@realDonaldTrump/posts/116166926920657651">said</a> on Truth Social.Energy markets were at the center of the volatility. Brent crude settled up 4.71%, while West Texas Intermediate crude gained 4.68%, after both contracts had surged more than 9% earlier in the session.Oil prices have rallied sharply since the conflict intensified, with Brent climbing more than 12% over two sessions as disruptions around the Strait of Hormuz threatened one of the world’s most critical oil shipping routes.&nbsp;Meanwhile, Tehran-backed Hezbollah launched missile and drone attacks toward Tel Aviv, and the U.S. embassy in Riyadh was&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.aljazeera.com/news/2026/3/3/us-embassy-in-saudi-capital-riyadh-hit-by-drones-fire-reported-ministry">reportedly</a> struck by drones. The U.S. State Department also ordered evacuations of some diplomatic staff from Bahrain, Iraq and Jordan.<h2 class="st-heading-2">Trending Stocks To Watch On NYSE, Nasdaq</h2>Micron Technology (MU): The stock is trending after Goldman Sachs raised its price target on the chipmaker to $360 from $235 while maintaining a “Neutral” rating. The company also began sending customers early samples of a new 256GB memory module built for AI data centers that deliver higher capacity while using less power.ImmunityBio (IBRX): The stock is in focus after the company warned of a&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-tumbles-after-hours-bcg-shortage-saudi-anktiva-launch-middle-east-tensions/cZd9PqbRI5R">“terrible” shortage</a> of BCG, a standard therapy for early-stage bladder cancer, and said it is preparing shipments of its immunotherapy Anktiva to Saudi Arabia amid rising geopolitical tensions.Battalion Oil (BATL): The stock is in focus after the company said it&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/battalion-oil-to-raise-15-million-batl-stock-surges-134-pre-market-amid-rising-crude-prices/cZde0BuRIPa">will raise</a> about $15 million from a new institutional investor through a share offering priced at $5.5.Trump Media &amp; Technology Group (DJT): The stock is trending amid intense community debate over President Donald Trump’s escalating military actions against Iran, with Stocktwits sentiment remaining “bearish” over the past three months amid “high” message volume.Sea (SE): The stock drew retail attention after the Singapore-based tech conglomerate reported mixed&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/se-stock-is-tumbling-today-after-mixed-q4-results/cZde0M8RIPO">fourth-quarter results</a>, with earnings missing analyst expectations even as revenue beat estimates.<h2 class="st-heading-2">How Global Markets Are Performing Today</h2>In broader markets, the yield on the benchmark 10-year U.S. Treasury note was near 4.06%, while gold traded around $5,136 after pulling back amid dollar strength.Asian markets fell on Wednesday, with MSCI’s broadest index of Asia-Pacific shares outside Japan dropping about 2.5%. South Korea’s Kospi declined about 4% and Japan’s Nikkei 225 slid about 2.5% for a third straight session of losses. Energy-importing economies such as Japan and South Korea are seen as particularly vulnerable to sustained rises in oil prices.Adam Kobeissi, founder of The Kobeissi Letter, also&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/TKL_Adam/status/2028872529541263833">noted on X</a> the broad market pressure across asset classes, saying, “The S&amp;P 500, Gold, Silver, Bitcoin, and Bonds are ALL down sharply. But why? What’s happening right now is a modest rush to the sidelines.”Among the catalysts for Wednesday are the ADP employment report, S&amp;P final U.S. services PMI, ISM services data and the Fed Beige Book, while investors will also watch quarterly earnings from Abercrombie &amp; Fitch, Broadcom and Okta.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Traders work on the floor of the New York Stock Exchange (NYSE) on March 02, 2026 in New York City. (Photo by Spencer Platt/Getty Images)

Dow, S&P 500, Nasdaq Futures Slip As Middle East War Fuels Oil Rally: Why MU, IBRX, BATL, DJT, SE Are On Traders’ Radar Today

Investors are looking at earnings from Abercrombie & Fitch, Broadcom and Okta on Wednesday.

Dow Jones, S&P 500, Nasdaq Futures Signal Another Weak Day On Wall Street: What’s Dragging US Stock Markets?

Equity

<ul class="summary-bullets"><li>ImmunityBio highlighted a “terrible” shortage of bladder-cancer therapy BCG with Merck as the lone global supplier.</li><li>Anktiva Saudi launch preparations are underway, with product shipments ready following two approvals from the Saudi FDA in January.</li><li>Net loss for FY25 narrowed to $351.4 million from $413.6 million in the previous year.</li></ul>Shares of ImmunityBio, Inc. (IBRX) fell more than 5% in extended trading on Tuesday after the drugmaker warned of a “terrible” shortage of&nbsp;a standard therapy for early-stage bladder cancer, noting that Merck &amp; Co., Inc. remains the sole supplier.The company&nbsp;also said it is preparing shipments of its immunotherapy Anktiva to Saudi Arabia amid rising geopolitical tensions in the region&nbsp;following recent U.S.-Israel military action on Iran.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> snapped three straight sessions of gains on Tuesday, declining over 4% to end at $10.<h2 class="st-heading-2">Anktiva Saudi Launch Preparations</h2>During its earnings call, ImmunityBio said product shipments for the Saudi launch are ready to commence following two approvals from the Saudi Food and Drug Authority in January. The company said it will work closely with local authorities to manage imports as it prepares to launch the therapy in the country despite “escalating circumstances” in the Middle East.“We recognize the ongoing global challenges, and especially those affecting the Middle East today, but cancer never pauses, and neither does ImmunityBio,” founder and executive chairman Patrick Soon-Shiong said.&nbsp;ImmunityBio was granted two approvals in January, covering both bladder cancer and metastatic non-small cell lung cancer. The lung cancer authorization allows Anktiva to be used in combination with checkpoint inhibitors for metastatic disease.The company also established a Saudi unit and partnered with regional distributors Biopharma and Cigalah to expand access across the Middle East and North Africa,&nbsp;which Soon-Shiong said represents “a significant and under-penetrated market for advanced immunotherapies.”<h2 class="st-heading-2">IBRX FY25 Review</h2>On Tuesday, ImmunityBio reported&nbsp;a full-year net loss of $351.4 million, narrowing from $413.6 million in 2024. The company posted net product revenue of $113 million for 2025, up 700% from the previous year, following the commercial rollout of Anktiva. The company attributed the growth to increasing clinical adoption rather than price increases, noting that unit sales volume rose about 750% during the year.Net product revenue rose to $38.3 million in the fourth quarter, up 20% from the previous quarter. The company said each quarter of 2025 delivered higher revenue than the prior period. ImmunityBio ended the year with $242.8 million in cash, cash equivalents, and marketable securities.&nbsp;<h2 class="st-heading-2">ImmunityBio’s Response To BCG Shortage</h2>The company highlighted the ongoing shortage of Bacillus Calmette-Guerin (BCG), the decades-old therapy widely used to treat non-muscle invasive bladder cancer. It noted that Merck is currently the only supplier of BCG globally.&nbsp;ImmunityBio pointed to its recombinant BCG program as a potential solution. The company said the U.S. Food and Drug Administration (FDA) authorized an expanded access program in February 2025 to help address the shortage of Tumor Immunotherapy with BCG.According to the drugmaker, the first patient was treated with recombinant BCG in March 2025, and 580 patients had been enrolled in the program as of February. The program now includes 100 clinical sites across academic centers and community urology practices, with “several thousand” doses administered either as monotherapy or in combination with Anktiva.ImmunityBio has requested a meeting with the FDA scheduled this month to discuss the next steps for recombinant BCG development.<h2 class="st-heading-2">ImmunityBio’s AI Push</h2>The company also outlined its internal AI platform, “Ask IB,” which integrates large language models and automated systems across its research and manufacturing operations.ImmunityBio said the platform is being used to support robotic manufacturing processes, scaling production of immune cell therapies while reducing contamination risk and enabling continuous production. It will also support predictive analytics across research and development and commercial operations.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX was ‘bullish’ amid ‘high’ message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_9bde4e221c.webp" alt="ibrx ss.png" width="971" height="142"><figcaption>IBRX sentiment and message volume as of March 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ISEEITALLTHETIME/message/646507904">said</a>, “I would say if orders are ready to ship to Saudi Arabia and Germany, I see no reason for any dilution. The revenues will continue to scale.”<stembedurl>https://stocktwits.com/ISEEITALLTHETIME/message/646507904</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/GordonGekko888/message/646507646">said</a>, “Earnings and earnings call were both GREAT. Ignore the crazy fluctuations which ALWAYS happen in biotech investing and we have a huge war going on in the Middle East effecting the mkts. All you have to do is HODL and get RICH!”<stembedurl>https://stocktwits.com/GordonGekko888/message/646507646</stembedurl>IBRX shares have climbed more than 400% year-to-date, far outperforming the Nasdaq’s 10% decline and the S&amp;P 500’s 0.5% gain.For updates and corrections, email newsroom[at]stocktwits[dot]com.

IBRX stock has surged over 400% year-to-date. (Representative image: Getty Images)

IBRX Stock Tumbles After-Hours: Flags ‘Terrible’ BCG Shortage As Saudi Anktiva Launch Nears Amid Middle East Tensions

To address the BCG shortage, ImmunityBio highlighted its recombinant BCG program, with 580 patients enrolled across about 100 clinical sites.

ImmunityBio Q4 Earnings Call Highlights

ImmunityBio (NASDAQ:IBRX) executives used the company's full-year 2025 earnings call to highlight a sharp ramp in ANKTIVA commercial revenue following U.S. approval, outline recent international...

ImmunityBio (NASDAQ:IBRX) Shares Down 4.2% - Should You Sell?

ImmunityBio (NASDAQ:IBRX) Shares Down 4.2% - Should You Sell...

Citigroup Inc. Decreases Stake in ImmunityBio, Inc. $IBRX

Citigroup Inc. lessened its stake in shares of ImmunityBio, Inc. (NASDAQ:IBRX - Free Report) by 4.2% in the third quarter, according to the company in its most recent Form 13F filing with the SEC...

<ul class="summary-bullets"><li>Founder and executive chairman Patrick Soon-Shiong called a rare public speech his “prelude” to Tuesday’s earnings update.</li><li>The company is set to report FY25 results on Tuesday, with estimates pointing to revenue of $113.3 million versus $14.8 million in 2024 and narrowing losses.</li><li>Anktiva generated $113 million in net product revenue in 2025, up 700% year over year, while Q4 revenue climbed 431% to $38.3 million.</li></ul>Shares of ImmunityBio, Inc. (IBRX) extended their three-day rally on Monday, with founder and executive chairman Patrick Soon-Shiong adding fuel to the stock by calling a rare public speech a “prelude” to its earnings update due Tuesday.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> rose nearly 7% on Monday to end at $10.44 and slipped slightly in extended trading.&nbsp;<h2 class="st-heading-2">IL-15 Spotlighted As Anktiva’s Core Engine</h2>Soon-Shiong&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2028658871623905656">said on X</a> that his remarks from last week, delivered at an event marking the 55th anniversary of President Richard Nixon’s “war on cancer,” were a “prelude” to ImmunityBio’s upcoming earnings.He criticized decades-old cancer treatment strategies, arguing that many chemotherapy drugs were developed without fully accounting for the immune system. He said high-dose chemo and radiation can significantly reduce vital immune cells like NK cells and T cells, creating a condition known as lymphopenia.&nbsp;He called the absolute lymphocyte count (ALC), a blood-test metric, “hidden in plain sight,” saying immune depletion has been underappreciated despite its measurability.Soon-Shiong also criticized major cancer drugs, citing Taxol, which is marketed by Bristol Myers, and Amgen’s Neupogen. He argued that these approaches reflected an industry-wide strategy of enabling more intensive chemotherapy and managing its side effects, rather than addressing underlying immune suppression.Against that backdrop, he spotlighted IL-15 as the biological engine behind Anktiva, positioning it as an immune amplifier rather than a traditional therapy. He contrasted older IL-2 approaches with IL-15 biology, saying IL-15 expands natural killer cells and memory cells without boosting immunosuppressive cells.&nbsp;<h2 class="st-heading-2">IBRX 2025 Results Preview</h2>ImmunityBio is set to report full-year&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-eyes-green-open-ahead-of-earnings-what-happened-with-anktiva-over-the-weekend/cZddUNHRIcl">2025 earnings</a> on Tuesday, with expectations for sharply higher revenue and narrowing losses as Anktiva's commercialization scales.Fiscal AI estimates 2025 revenue of $113.29 million, up from $14.75 million in 2024, with loss per share improving to $0.38 from $0.59. The company has indicated $113 million in net product revenue for Anktiva in 2025, up 700% year over year, while fourth-quarter revenue rose 431% to $38.3 million, topping estimates. Full-year net loss attributable to common shareholders improved to $351.4 million from $413.6 million in 2024.<h2 class="st-heading-2">Regulatory Wins Bolster Anktiva Outlook</h2>Soon-Shiong has recently amplified Anktiva’s IL-15 mechanism in national media appearances and highlighted combination approaches with checkpoint inhibitors such as Merck’s Keytruda.&nbsp;ImmunityBio recently completed enrollment ahead of schedule in its Phase 2 Quilt 2.005 trial evaluating Anktiva plus BCG in early-stage bladder cancer, citing improved cancer-free rates compared with standard BCG alone. A biologics license application for the regimen is expected by the fourth quarter of 2026.Anktiva is already approved in combination with BCG for bladder cancer in the U.S. and has received authorizations in the UK, Europe, and Saudi Arabia, where regulators also granted accelerated approval for use with a checkpoint inhibitor in metastatic non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX was ‘bullish’ amid a 185% jump in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_09ff793a38.webp" alt="ibrx ss.png" width="967" height="144"><figcaption>IBRX sentiment and message volume as of March 3 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/PureLand/message/646395463">said</a> that, “If [broader Saudi] approval comes through, the stock could jump toward $20 quickly, and a squeeze could drive it over $100.”<stembedurl>https://stocktwits.com/PureLand/message/646395463</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/MrStockxy/message/646392467">said</a>, “Will be go[ing to] $11 tomorrow. Let’s bet.”<stembedurl>https://stocktwits.com/MrStockxy/message/646392467</stembedurl>IBRX stock has surged over 400% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the ImmunityBio logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

IBRX Stock Extends Rally To Day 3: Founder Drops ‘Prelude’ To 2025 Earnings, Slams Bristol Myers, Amgen Cancer Playbook

The founder criticized traditional chemotherapy approaches from Amgen and Bristol Myers and hyped up the mechanism behind Anktiva.

ImmunityBio (NASDAQ:IBRX) Trading 6.7% Higher Following Better-Than-Expected Earnings

ImmunityBio (NASDAQ:IBRX) Stock Price Up 6.7% Following Earnings Beat...

Biotech Stocks To Follow Today - March 2nd

Danaher, Moderna, and ImmunityBio are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop, and...

ImmunityBio Target of Unusually High Options Trading (NASDAQ:IBRX)

ImmunityBio, Inc. (NASDAQ:IBRX - Get Free Report) was the target of some unusual options trading activity on Monday. Stock investors purchased 48,270 call options on the company. This represents an...

<ul class="summary-bullets"><li>The company's 2025 outlook shows EBIT loss narrowing to $256.03 million from $344.18 million a year ago.</li><li>Anktiva commercialization is driving traction, with 2025 net product revenue reaching $113 million, up 700% from the previous year.</li><li>ImmunityBio's Phase 2 Quilt 2.005 data shows higher cancer-free rates and a potential BLA filing expected by Q4.</li></ul>Shares of ImmunityBio, Inc. (IBRX) jumped 1% in overnight trading Sunday as investors positioned ahead of Tuesday’s earnings, with fresh weekend buzz around Anktiva following founder Patrick Soon-Shiong’s media appearances.<a href="https://stocktwits.com/symbol/IBRX">IBRX stock</a> jumped over 2% on Friday to $0.78 and added another 5% in after-hours trading.&nbsp;<h2 class="st-heading-2">Earnings Expectations Take Center Stage</h2>ImmunityBio is set to report its full-year 2025 earnings on Tuesday, with expectations building that losses may narrow as the company scales commercialization of Anktiva, its lead immunotherapy.Fiscal AI estimates for 2025 show an improvement across all metrics. Revenue is projected to rise to $113.29 million from $14.75 million in 2024, while earnings before interest and taxes (EBIT)&nbsp;are expected to narrow to a loss of $256.03 million from $344.18 million a year ago. Loss per share is forecast to improve to $0.38 from $0.59 in 2024.The company has already indicated strong commercial traction&nbsp;for Anktiva, recording $113 million in net product revenue for the drug in 2025, up 700% from the prior year, while fourth-quarter (Q4) revenue rose 431% to $38.3 million, topping Wall Street estimates of $37.8 million.Despite higher research spending pushing Q4 net loss to $61.9 million from $59.2 million, full-year net loss attributable to common shareholders improved to $351.4 million from a loss of $413.6 million in 2024.<h2 class="st-heading-2">Founder Highlights Anktiva On National TV</h2>Over the weekend, founder and executive chairman Patrick Soon-Shiong amplified the scientific importance of Anktiva through a series of national&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-retail-frenzy-founder-prime-time-tv-blitz-retail-saudi-funding-trump-tailwinds/cZTc3BORIRN">media appearances</a>, including an interview with Fox News Chief Political Anchor Bret Baier and participation in a live discussion with Christopher Cuomo on NewsNation.Reflecting on conversations aired during a segment focused on cancer research and treatment, Soon-Shiong highlighted&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://x.com/DrPatrick/status/2028173238338204093">on X</a> the importance of IL-15, the biological foundation of Anktiva, noting its ability to stimulate T cells, NK cells and memory T cells, which supports durable immune responses across multiple tumor types.Soon-Shiong also pointed to remarks from U.S. Food and Drug Administration (FDA) authorities that a validated mechanism of action can support additional indications, and highlighted the agency’s “plausible mechanism of action” pathway as a means to accelerate access to therapies such as IL-15. He added that results from the company’s Quilt trials in lung, breast, and pancreatic cancers showed that IL-15 has the potential to generate long-term immune memory.The founder also drew attention to combination approaches involving Anktiva and Merck’s Keytruda. He said checkpoint inhibitors such as Merck’s Keytruda work by removing the “brakes” on immune cells, while Anktiva helps grow and strengthen those immune cells. He said the combination could help patients respond if their cancer stops reacting to earlier immunotherapy.<h2 class="st-heading-2">Trial Progress Adds Momentum</h2>ImmunityBio recently completed enrollment ahead of schedule in its Phase 2 Quilt 2.005 trial evaluating Anktiva combined with BCG in patients with early-stage bladder cancer who had not previously received standard BCG therapy.The study enrolled 366 patients and an early FDA-requested review indicated improved outcomes with the combination. After six months, 85% of patients receiving Anktiva with BCG remained cancer-free compared with 57% treated with BCG alone. At nine months, 84% of patients on the combination showed no recurrence, compared with 52% on standard therapy.The company expects to submit a biologics license application for the regimen by the fourth quarter of 2026. Anktiva is already approved in combination with BCG for bladder cancer in the U.S. and has also received authorizations in the UK, Europe and Saudi Arabia. Saudi regulators recently granted accelerated approval for the therapy in combination with a checkpoint inhibitor in metastatic non-small cell lung cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for IBRX shifted from ‘extremely bullish’ to ‘bullish’ amid a 65% decline in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ibrx_ss_png_3d2d4b49a6.webp" alt="ibrx ss.png" width="975" height="143"><figcaption>IBRX sentiment and message volume as of March 2 | Source: Stocktwits</figcaption></figure>One user noted that Keytruda currently generates more than $30 billion in annual sales and is set to face patent expiration in 2028, describing Anktiva as a “better” product that could benefit from that shift. They urged traders to “buy and hold” the stock.<stembedurl>https://stocktwits.com/Johann1011/message/646276968</stembedurl>Another user said, “I look forward to tomorrow's trading day. Things look promising for IBRX!!”<stembedurl>https://stocktwits.com/BullriderNkg/message/646274508</stembedurl>IBRX stock has skyrocketed nearly 400% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Dr. Patrick Soon-Shiong announces newest initiatives for Cancer MoonShot 2020 at Hyatt Regency Boston on October 26, 2016. (Photo by Darren McCollester/Getty Images for NantHealth, Inc.)

IBRX Stock Eyes Green Open Ahead Of Earnings — What Happened With Anktiva Over The Weekend

Founder Patrick Soon-Shiong spotlighted Anktiva on national TV, emphasizing IL-15’s potential to activate the immune system and its combination approach with Merck’s Keytruda.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Software / SaaS

Cybersecurity

Cloud Infrastructure

AI / Semiconductors

Which beaten-down sector are you buying first?

Stocktwits

Stocktwits Polls

Revolutionary treatments leveraging NK cells and AI for broad application against cancer, aiming to shift global health paradigms with promising new approvals.

The company confirms imminent product shipments to Germany and Saudi Arabia, alongside US government interest in Dunkirk facilities for national biodefense.

CEO compares the company's growth trajectory and disruptive potential to that of giants like Tesla and Nvidia, highlighting long-term organic value.

Despite an after-hours dip, strong convictions suggest shorts are increasingly "trapped" by high interest and underlying fundamentals, potentially leading to a squeeze.

Following the earnings call, many investors see the after-hours price drop as an opportunistic chance to "load up" shares before an anticipated rebound.

IBRX
ImmunityBio Inc

Feed

News

Sentiment

Fundamentals

Info

Latest IBRX News

IBRXImmunityBio Inc